4.7 Review

Patient-tailored antithrombotic therapy following percutaneous coronary intervention

期刊

EUROPEAN HEART JOURNAL
卷 42, 期 10, 页码 1038-+

出版社

OXFORD UNIV PRESS
DOI: 10.1093/eurheartj/ehaa1097

关键词

Dual antiplatelet therapy; Patient-tailored antithrombotic therapy; Risk stratification

向作者/读者索取更多资源

Dual antiplatelet therapy is the standard of care for patients with chronic coronary syndrome and acute coronary syndrome undergoing percutaneous coronary intervention, but selecting the optimal duration and composition of treatment poses a major challenge. Current guidelines recommend risk stratification for tailoring treatment, yet various risk scoring methods and testing approaches have not been widely adopted in clinical practice. Further research and validation are needed to determine the effectiveness of these risk stratification methods in improving clinical outcomes.
Dual antiplatelet therapy has long been the standard of care in preventing coronary and cerebrovascular thrombotic events in patients with chronic coronary syndrome and acute coronary syndrome undergoing percutaneous coronary intervention, but choosing the optimal treatment duration and composition has become a major challenge. Numerous studies have shown that certain patients benefit from either shortened or extended treatment duration. Furthermore, trials evaluating novel antithrombotic strategies, such as P2Y(12) inhibitor monotherapy, low-dose factor Xa inhibitors on top of antiplatelet therapy, and platelet function- or genotype-guided (de-)escalation of treatment, have shown promising results. Current guidelines recommend risk stratification for tailoring treatment duration and composition. Although several risk stratification methods evaluating ischaemic and bleeding risk are available to clinicians, such as the use of risk scores, platelet function testing, and genotyping, risk stratification has not been broadly adopted in clinical practice. Multiple risk scores have been developed to determine the optimal treatment duration, but external validation studies have yielded conflicting results in terms of calibration and discrimination and there is limited evidence that their adoption improves clinical outcomes. Likewise, platelet function testing and genotyping can provide useful prognostic insights, but trials evaluating treatment strategies guided by these stratification methods have produced mixed results. This review critically appraises the currently available antithrombotic strategies and provides a viewpoint on the use of different risk stratification methods alongside clinical judgement in current clinical practice. [GRAPHICS]

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据